ABCL icon

AbCellera Biologics

2.22 USD
+0.13
6.22%
At close Apr 2, 4:00 PM EDT
After hours
2.12
-0.10
4.50%
1 day
6.22%
5 days
-8.26%
1 month
-5.93%
3 months
-26.73%
6 months
-10.48%
Year to date
-26.73%
1 year
-48.61%
5 years
-96.23%
10 years
-96.23%
 

About: AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Employees: 596

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

22% more capital invested

Capital invested by funds: $273M [Q3] → $334M (+$60.7M) [Q4]

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

6% more funds holding

Funds holding: 138 [Q3] → 146 (+8) [Q4]

2.9% more ownership

Funds ownership: 35.65% [Q3] → 38.56% (+2.9%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

25% less call options, than puts

Call options by funds: $973K | Put options by funds: $1.3M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
80%
upside
Avg. target
$7
215%
upside
High target
$10
350%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Stephen Willey
30% 1-year accuracy
6 / 20 met price target
350%upside
$10
Buy
Maintained
28 Feb 2025
Keybanc
Scott Schoenhaus
19% 1-year accuracy
6 / 31 met price target
80%upside
$4
Overweight
Maintained
8 Jan 2025

Financial journalist opinion

Neutral
Business Wire
1 week ago
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025.
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
Neutral
Seeking Alpha
1 month ago
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Steve Dechert - KeyBanc Jacqueline Kisa - TD Securities Malcolm Hoffman - BMO Capital Markets Operator Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast.
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.17 per share a year ago.
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
AbCellera Reports Full Year 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2024 Business Results.
AbCellera Reports Full Year 2024 Business Results
Neutral
Business Wire
1 month ago
AbCellera to Participate at Upcoming Investor Conferences in March
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in March.
AbCellera to Participate at Upcoming Investor Conferences in March
Neutral
Business Wire
2 months ago
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025.
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
Neutral
Business Wire
2 months ago
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology.
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
Positive
Seeking Alpha
3 months ago
AbCellera Biologics: Still A Concept Stock
Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet.
AbCellera Biologics: Still A Concept Stock
Neutral
Business Wire
4 months ago
AbCellera to Present at Upcoming Investor Conferences in December and January
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in December and January.
AbCellera to Present at Upcoming Investor Conferences in December and January
Neutral
Business Wire
4 months ago
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Charts implemented using Lightweight Charts™